Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lattice Biologics Ltd LBLTF


Primary Symbol: V.LBL.H

Healthcare Biotechnology
Lattice Biologics Ltd. is engaged in the business of developing, manufacturing and marketing biologics products to domestic and international markets. The Company’s products are used in a variety of applications including enhancing bone regeneration in dental, spine, and general orthopedic indications. Its acellular dermal matrix is used for dental flaps which is used to close defects post... see more

Recent & Breaking News (TSXV:LBL.H)

AmnioVisc™: a transformational breakthrough for Lattice Biologics

Jeff Nielson October 13, 2016

Lattice Biologics Launches AmnioVisc(TM) All Natural Amniotic Fluid Supplement for Arthritic Joints

MarketWire Canada October 11, 2016

Lattice Biologics Issues Common Shares Pursuant to Shares for Services Agreements

MarketWire Canada October 11, 2016

Lattice Biologics Closes First Tranche of Private Placement Announced on September 13, 2016

MarketWire Canada September 15, 2016

Lattice Biologics Announces New Private Placement and Eliminates Can$1.8 Million in Debt

MarketWire Canada September 13, 2016

New Vendor Approval Gives Lattice Biologics Access to 39 Additional Hospitals

MarketWire Canada September 6, 2016

Lattice Biologics Ltd. Reports Third Quarter 2016 Highlights

MarketWire Canada August 29, 2016

Notice of Lattice Biologics Ltd. Third Quarter 2016 Financial Results Conference Call

MarketWire Canada August 23, 2016

Lattice Biologics Issues Common Shares

MarketWire Canada August 15, 2016

Lattice Biologics Announces Planned Debt-to-Equity Conversion

MarketWire Canada August 10, 2016

Lattice Biologics Completes $500k Private Placement Announced on June 28, 2016

MarketWire Canada August 8, 2016

Giving Surgeons What They Want: 7 New Products From Lattice Biologics

MarketWire Canada August 4, 2016

Lattice Biologics Gains "Preferred Vendor Status" With the Veterans Health Administration (VHA)

MarketWire Canada August 1, 2016

Lattice Biologics Announces Senior Management Change

MarketWire Canada July 15, 2016

Lattice Biologics Announces New Private Placement

MarketWire Canada June 29, 2016

Latest Vendor Approval Gives Lattice Biologics Access to Another 16 Hospitals

MarketWire Canada June 20, 2016

Latest Vendor Approval Gives Lattice Biologics Access to Another 16 Hospitals

Marketwired June 20, 2016

Major Southwest Hospital Group Designates Lattice Biologics as Approved Vendor

Marketwired June 9, 2016

Lattice Biologics Ltd. Reports Second Quarter 2016 Highlights

Marketwired May 26, 2016

Lattice Biologics (V.LBL) CEO moves to revolutionize cancer diagnosis

Gaalen Engen April 27, 2016